Immediate Impact

3 standout
Sub-graph 1 of 2

Citing Papers

Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches
2023 Standout
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
2023 Standout
1 intermediate paper

Works of Isabelle Rieger being referenced

A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
2021
LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
2021

Author Peers

Author Last Decade Papers Cites
Isabelle Rieger 62 21 12 29 26 7 90
Ihor Sawczuk 82 17 4 14 56 7 113
Cristina Zuliani 24 22 23 12 39 9 169
Anna Ratiu 56 14 27 33 7 171
Louis Marie Dourthe 101 57 3 30 87 5 172
Antonio Verde 114 37 3 25 62 12 181
Martin Russell 66 30 1 26 32 9 109
Delphine Gourcerol 47 77 9 26 6 195
M. Button 129 82 2 41 20 12 174
Yen-Chuan Ou 65 35 11 17 22 6 116
T Onishi 85 16 17 14 8 96

All Works

Loading papers...

Rankless by CCL
2026